Compugen (XTAE:CGEN) FFO


XTAE:CGEN Compugen Ltd XTAE:CGEN
58 GF Score
Price ₪7.00
GF Value ₪15.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen FFO?

FFO (Funds from operations) only applies to REITs.

XTAE:CGEN
58GF Score
Compugen Ltd XTAE:CGEN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Compugen (XTAE:CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of ₪7.00 is trading 55.5% below its estimated GF Value™ of ₪15.74. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for XTAE:CGEN:

  • FFO:
  • GF Value™: ₪15.74 vs. price of ₪7.00 (55.5% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the XTAE:CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compugen Business Description

Other Exchanges CGEN:USA
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
58GF Score

Get the complete analysis for XTAE:CGEN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪7.00
Price
₪15.74
GF Value